Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Allarity Therapeutics, Inc. ( (ALLR) ) just unveiled an announcement.
Allarity Therapeutics, Inc. has updated its financing strategy by amending an agreement to potentially sell up to $50 million in common stock through Ascendiant Capital Markets, LLC. Simultaneously, the company announced a key executive change, appointing Alexander Epshinsky as the new CFO after Joan Y. Brown’s departure. Epshinsky brings extensive experience in finance, previously serving in high-level accounting roles at several biotech firms. His employment agreement includes a competitive salary, bonus potential, equity incentives, and severance terms. With these changes, Allarity Therapeutics is poised to explore various financing opportunities to support its growth and strategic objectives.
Find detailed analytics on ALLR stock on TipRanks’ Stock Analysis page.
